Amicoumacin B

CAS : 77674-99-8

Ref. 3D-AA177129

Informations sur le produit

• Nom: Amicoumacin B
• Synonymes: (3S,4S,5S)-3-ammonio-4,5-dihydroxy-6-({(1S)-1-[(3S)-8-hydroxy-1-oxo-3,4-dihydro-1H-isochromen-3-yl]-3-methylbutyl}amino)-6-oxohexanoate (non-preferred name), 3-Amino-2,3,6-trideoxy-6-[[(1S)-1-[(3S)-3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl]-3-methylbutyl]amino]-6-oxo-<span class="text-smallcaps">D</span>-ribo-hexonic acid, <span class="text-smallcaps">D</span>-ribo-Hexar-6-amic acid, 3-amino-2,3-dideoxy-N-[1-(3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]-, [S-(R*,R*)]-, <span class="text-smallcaps">D</span>-ribo-Hexonic acid, 3-amino-2,3,6-trideoxy-6-[[(1S)-1-[(3S)-3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl]-3-methylbutyl]amino]-6-oxo-, Ai 77B, 3-Amino-2,3,6-trideoxy-6-[[(1S)-1-[(3S)-3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl]-3-methylbutyl]amino]-6-oxo-D-ribo-hexonic acid, D-ribo-Hexar-6-amic acid, 3-amino-2,3-dideoxy-N-[1-(3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]-, [S-(R*,R*)]-, D-ribo-Hexonic acid, 3-amino-2,3,6-trideoxy-6-[[(1S)-1-[(3S)-3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl]-3-methylbutyl]amino]-6-oxo-

Description

Amicoumacin B is a complex antibiotic that has high cytotoxicity against subtilis and other species of bacteria. It is an asymmetric synthesis of two molecules, amicoumacin A and amicoumacin B, which are both produced by the bacterium Streptomyces sp. Amicoumacin B has been shown to be a potent inhibitor of cervical cancer cells in vitro. This antibiotic is composed of a hydroxyl group and an ester linkage between the hydroxycarboxylic acid moiety and the amino moiety. It has been shown to have a high blood level in humans, with a type strain from human plasma showing an enantiomer ratio of 97:3 in favor of the levo-amino acid. The genus Streptomyces includes many species including S. griseus, S. lividans, S. viridochromogenes, and S. violaceoruber.
END>

• Marque: Biosynth

Propriétés chimiques

• Degré de pureté: Min. 95%